201 related articles for article (PubMed ID: 17060859)
21. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
Markasz L; Stuber G; Flaberg E; Jernberg AG; Eksborg S; Olah E; Skribek H; Szekely L
BMC Cancer; 2006 Nov; 6():265. PubMed ID: 17101045
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
Taylor AL; Marcus R; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
[TBL] [Abstract][Full Text] [Related]
23. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
24. Meningioma: is there an association with human leukocyte antigens?
Machulla HK; Steinborn F; Tschigrjai M; Langner J; Rainov NG
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1438-42. PubMed ID: 14693734
[TBL] [Abstract][Full Text] [Related]
25. Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients.
Liu D; Tammik C; Zou JZ; Ernberg I; Masucci MG; Ringden O; Levitsky V
Clin Transplant; 2004 Oct; 18(5):518-24. PubMed ID: 15344953
[TBL] [Abstract][Full Text] [Related]
26. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
Katz BZ; Pahl E; Crawford SE; Kostyk MC; Rodgers S; Seshadri R; Proytcheva M; Pophal S
Pediatr Transplant; 2007 Feb; 11(1):58-65. PubMed ID: 17239124
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
28. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
30. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
31. Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient.
Brunner B; Kropshofer G; Ellemunter H; Brunner A; Mueller T; Margreiter R; Tzankov A
Pediatr Transplant; 2007 Aug; 11(5):547-51. PubMed ID: 17631026
[TBL] [Abstract][Full Text] [Related]
32. Treatment for Epstein-Barr virus-associated PTLD.
Gross TG
Herpes; 2009 Jan; 15(3):64-7. PubMed ID: 19306606
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.
Capello D; Rasi S; Oreste P; Veronese S; Cerri M; Ravelli E; Rossi D; Minola E; Colosimo A; Gambacorta M; Muti G; Morra E; Gaidano G
J Pathol; 2009 Aug; 218(4):478-86. PubMed ID: 19391128
[TBL] [Abstract][Full Text] [Related]
34. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
[TBL] [Abstract][Full Text] [Related]
35. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.
Preiksaitis JK; Keay S
Clin Infect Dis; 2001 Jul; 33 Suppl 1():S38-46. PubMed ID: 11389521
[TBL] [Abstract][Full Text] [Related]
37. Utility of head and neck biopsies in the evaluation of posttransplant lymphoproliferative disorder.
Campisi P; Allen UD; Ngan BY; Hawkes M; Forte V
Otolaryngol Head Neck Surg; 2007 Aug; 137(2):296-300. PubMed ID: 17666259
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients.
Babel N; Schwarzmann F; Pruss A; Volk HD; Reinke P
Transplant Proc; 2004 Nov; 36(9):2679-82. PubMed ID: 15621122
[TBL] [Abstract][Full Text] [Related]
39. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
40. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
